

REFERENCES

- 1 Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine 5'-monophosphate in asthmatic patients. *Am J Respir Crit Care Med* 1999; 160: 237-243
- 2 Prosperini G, Rajakulasingam K, Cacciola RR, et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. *J Allergy Clin Immunol* 2002; 110:855-861
- 3 Phillips K, Osborne J, Lewis S, et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. *Thorax* 2004; 59:26-30
- 4 Polosa R, Li Gotti F, Mangano G, et al. Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. *Clin Exp Allergy* 2003; 33:873-881
- 5 Prieto L, Bruno L, Gutierrez V, et al. Airway responsiveness to AMP and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. *Chest* 2003; 124:1325-1333
- 6 Spicuzza L, Bonfiglio C, Polosa R. Research applications and implications of adenosine in diseased airways. *Trends Pharmacol Sci* 2003; 24:409-413

Monitoring the Adjustment of Antiasthma Medications With Adenosine Monophosphate Bronchoprovocation

To the Editor:

We would like to thank Dr. Proietti and colleagues for their interest and stimulating comments on our article.¹ We certainly agree with them that an alternative analysis utilizing a cut-off point of three doubling concentrations decrease in the provocative concentration causing a 20% fall in FEV₁ (PC₂₀) with adenosine 5'-monophosphate (AMP) 2 weeks after halving the dose of inhaled corticosteroids (ICS) would provide different results. However, only one of our patients showed a decrease in PC₂₀ of three or more doubling concentrations 2 weeks after the dose of ICS was halved.

Dr Proietti states that, "by arbitrarily setting the cut-off values for PC₂₀ AMP at baseline too high (400 mg/mL), there is the chance of including very mild asthmatic patients who are unlikely to develop exacerbations." We regret that our description of patient characteristics has led to misunderstanding. Our study examined the utility of the determination of airway responsiveness to AMP and exhaled nitric oxide levels as markers for safely reducing the dose of ICS. Thus, we selected patients with stable asthma in good control with ICS, but not subjects with mild asthma. Although asthma control is often used to define asthma severity, this assumption is incorrect.² A significant proportion of patients included in our study had moderate-to-severe asthma, but were well controlled with ICS at medium-to-high doses (beclomethasone, 500 to 1,000 µg or equivalent daily).

Finally, Proietti et al state that it could have been of critical importance to include methacholine provocation in the protocol. In a previous study,³ we have shown that the detection of a plateau on the concentration-response curve to methacholine, but not the PC₂₀ value, may be used as a marker for safely reducing the corticosteroid dose. However, it is clear that further studies are needed to clarify the potential value of the determi-

nation of the response to both methacholine and AMP as a means to identifying those asthmatic patients whose conditions will or will not deteriorate when the dose of ICS is reduced.

Luis Prieto, MD, PhD
Hospital Universitario Dr Peset
Valencia, Spain

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: permissions@chestnet.org).

Correspondence to: Luis Prieto, MD, PhD, Seccion de Alergología, Hospital Universitario Dr Peset, C/ Gaspar Aguilar 90, 46017 Valencia, Spain; e-mail: prieto_jes@gva.es

REFERENCES

- 1 Prieto L, Bruno L, Gutiérrez V, et al. Airway responsiveness to adenosine 5'-monophosphate and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. *Chest* 2003; 124:1325-1333
- 2 Cockcroft DW, Swystun VA. Asthma control versus asthma severity. *J Allergy Clin Immunol* 1996; 98:1016-1018
- 3 Prieto L, Gutiérrez V, Morales C. Maximal response plateau to methacholine as a reliable index for reducing inhaled budesonide in moderate asthma. *Eur Respir J* 1999; 13:1236-1244

Heartbeat Synchronizes With Respiratory Rhythm Only Under Specific Circumstances

To the Editor:

Yasuma and Hayano (February 2004)¹ have theorized that respiratory sinus arrhythmia improves respiratory efficiency by the pairing of increases in heart rate with inhalation, when the concentration of oxygen in the alveoli is maximal. However, this phase relationship only occurs under specific circumstances.

Saul et al² applied vagal and sympathetic blocking agents, and found that the phase lag from breathing to heart rate is near 0°, but only under pure vagal conditions. Under pure sympathetic conditions, the phase relationship varies from 180° at low frequencies to approximately -180° at high frequencies.

We asked eight healthy subjects to breathe at seven frequencies between 0.04 and 0.5 Hz for 2 min each, matching their strain-gauge respiration record to a computer-generated sine curve³ to ensure a constant respiratory depth and a sinusoidal shape for respiratory curves. Using Fourier filtration,³ we determined that the phase relationship between heart rate and respiration was 0° only at a respiratory frequency of approximately 0.1 Hz, in which the target frequency heart rate variability also was highest (Fig 1).

When healthy people breathe regularly at this resonant frequency for the cardiovascular system, we also found that the baroreflexes are systematically stimulated and baroreflex gain increases.⁴ In addition, peak expiratory flow improves.⁴ There also is preliminary evidence for an improvement in clinical asthma,⁵ and for improvement in respiratory gas exchange efficiency and clinical function in COPD patients.⁶

Thus, the hypothesis of Yasuma and Hayano¹ would be specifically relevant for sympathetically medicated heart rate variabil-




FIGURE 1. Transfer function of respiration (input) to heart rate (output). Values given as the mean of eight subjects.

ity, or for respiratory sinus arrhythmia associated with slow breathing at approximately 0.1 Hz.

Evgeny Vaschillo, PhD
Bronya Vaschillo, PhD
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
Piscataway, NJ
Paul Lehrer, PhD
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
Piscataway, NJ

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: permissions@chestnet.org).
 Correspondence to: Paul Lehrer, PhD, Department of Psychiatry, D-335, UMDNJ-Robert Wood Johnson Medical School, 671 Hoes Ln, Piscataway, NJ 08854; e-mail: lehrer@umdnj.edu

REFERENCES

- 1 Yasuma F, Hayano J. Respiratory sinus arrhythmia: why does the heartbeat synchronize with respiratory rhythm? *Chest* 2004; 125:683–690
- 2 Saul JP, Berger RD, Albrecht P, et al. Transfer function analysis of the circulation: unique insights into cardiovascular regulation. *Am J Physiol Heart Circ Physiol* 1991; 261: H1231–H1245
- 3 Vaschillo E, Lehrer P, Rishé N, et al. Heart rate variability biofeedback as a method for assessing baroreflex function: a preliminary study of resonance in the cardiovascular system *Appl Psychophysiol Biofeedback* 2002; 27:1–27
- 4 Lehrer PM, Vaschillo E, Vaschillo B, et al. Heart rate variability biofeedback increases baroreflex gain and peak expiratory flow. *Psychosom Med* 2003; 65:796–805
- 5 Lehrer PM, Vaschillo E, Vaschillo B, et al. Biofeedback treatment for asthma. *Chest* 2004; 126:352–361
- 6 Giardino N, Chan L, Borson S. Combined heart rate variability and pulse oximetry biofeedback for chronic obstructive

pulmonary disease: a feasibility study. *Appl Psychophysiol Biofeedback* 2004; 29:121–133

To the Editor:

We appreciate the interest by Drs. Vaschillo and Lehrer in our Opinions/Hypothesis article (February 2004)¹ on respiratory sinus arrhythmia (RSA). We agree with their comment that heartbeat synchronizes with respiratory rhythm only under certain conditions, so that the results of the physiologic experiment are only applicable to the model used in the study. In their well-organized investigation,² Vaschillo and coworkers² used healthy subjects who were strictly instructed to breathe in synchrony with the extrinsic pacemaker (*ie*, a metronome) at predetermined respiratory frequencies between 0.04 and 0.5 Hz for 2 min. As was noted in our Opinions/Hypothesis article,¹ humans are a species with a weak RSA compared with dogs. Moreover, a paced breathing that is in synchrony with the extrinsic rhythm generator might precipitate mental stress for subjects, and the equilibrium state of CO₂/O₂ metabolism through the paced breathing could not have been obtained in a very short period of time. Such factors as species, state of the subjects (*ie*, very alert, alert, relaxed, or asleep), and metabolism should always be considered in clinical/basic experiments on the synchrony of heartbeat with respiratory rhythm. Therefore, for this purpose we used trained dogs to lie down in a relaxed state under spontaneous breathing,^{3–5} as dogs are a species with a strong RSA.

The phase relationship between heart rate and respiration shows frequency dependence, but the relationship is known to be nonlinear.⁶ Eckberg⁶ has reported that the phase analysis between heart rate and respiration shows a clear hysteresis, and that the prolongation of the R-R interval begins shortly after the onset of expiration independently of respiratory frequency. He has also demonstrated that the shortening of the R-R interval begins progressively earlier in reference to the onset of inspiration as respiratory frequency decreases. As a result, the timing of the maximum instantaneous heart rate occurs instantly after end-inspiration, with the maximal lung volume at least for a respiratory frequency of < 0.25 Hz. Although the phase of the maximum heart rate lags behind the phase of the maximum lung volume as respiratory frequency increases, the amplitude of RSA decreases progressively.⁷ These facts seem to be consistent with the hypothesis that RSA is a function of physiologic respite for the cardiovascular and respiratory systems in resting animals and humans, because the phase relationship at a reduced respiratory frequency is optimal to cardiac and respiratory energy savings by reducing unnecessary heartbeats during expiration and unnecessary ventilation during the waning phase of the heart beat.^{1,8}

Fumihiko Yasuma, MD, FCCP
Suzuka National Hospital
Suzuka, Japan
Jun-ichiro Hayano, MD, FCCP
Nagoya City University School of Medicine
Nagoya, Japan

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: permissions@chestnet.org).
 Correspondence to: Fumihiko Yasuma, MD, FCCP, Suzuka National Hospital, 3-2-1 Kasado, Suzuka, Japan 513-8501; e-mail: f-yasuma@mtb.biglobe.ne.jp

REFERENCES

- 1 Yasuma F, Hayano J. Respiratory sinus arrhythmia: why does the heartbeat synchronize with respiratory rhythm? *Chest* 2004; 125:683–690